ScoreComparison
Why is Kiora Pharmaceuticals, Inc. ?
Unrated Stock - No Analysis Available
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-6.27%
EBIT to Interest (avg)
-7.32
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.01
Sales to Capital Employed (avg)
0.42
Tax Ratio
22.18%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
47.57%
ROCE (avg)
35.43%
ROE (avg)
3.98%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.40
EV to EBIT
1.16
EV to EBITDA
1.17
EV to Capital Employed
14.66
EV to Sales
-14.66
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
1262.96%
ROE (Latest)
-44.68%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend0What is working for the Company
NO KEY POSITIVE TRIGGERS
-9What is not working for the Company
NET PROFIT(HY)
At USD -3.93 MM has Grown at -134.68%
RAW MATERIAL COST(Y)
Grown by 110.4% (YoY
Here's what is not working for Kiora Pharmaceuticals, Inc.
Net Profit
At USD -3.93 MM has Grown at -134.68%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very negative
Net Profit (USD MM)
Raw Material Cost
Grown by 110.4% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
